Below are the most recent publications written about "Factor Xa" by people in Profiles.
-
Imran JB, Madni TD, Clark AT, Rizk P, Huang E, Minshall CT, Taveras LR, Cunningham HB, Eastman AL, Koshy JP, Kacir CD, Cripps MW. Inability to predict subprophylactic anti-factor Xa levels in trauma patients receiving early low-molecular-weight heparin. J Trauma Acute Care Surg. 2018 11; 85(5):867-872.
-
Kastelowitz N, Tamura R, Onasoga A, Stalker TJ, White OR, Brown PN, Brodsky GL, Brass LF, Branchford BR, Di Paola J, Yin H. Peptides derived from MARCKS block coagulation complex assembly on phosphatidylserine. Sci Rep. 2017 06 27; 7(1):4275.
-
Sarich TC, Seltzer JH, Berkowitz SD, Costin' J, Curnutte JT, Gibson CM, Hoffman M, Kaminskas E, Krucoff MW, Levy JH, Mintz PD, Reilly PA, Sager PT, Singer DE, Stockbridge N, Weitz JI, Kowey PR. Novel oral anticoagulants and reversal agents: Considerations for clinical development. Am Heart J. 2015 Jun; 169(6):751-7.
-
Palladino M, Thomson L, Swift B, Merli GJ. Implementing the new oral anticoagulants into the hospital formulary. Am J Hematol. 2012 May; 87 Suppl 1:S127-32.
-
Ivanciu L, Toso R, Margaritis P, Pavani G, Kim H, Schlachterman A, Liu JH, Clerin V, Pittman DD, Rose-Miranda R, Shields KM, Erbe DV, Tobin JF, Arruda VR, Camire RM. A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia. Nat Biotechnol. 2011 Oct 23; 29(11):1028-33.
-
Galanis T, Kraft WK, Merli GJ. Prophylaxis for deep vein thrombosis and pulmonary embolism in the surgical patient. Adv Surg. 2011; 45:361-90.
-
Rowan BO, Kuhl DA, Lee MD, Tichansky DS, Madan AK. Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin. Obes Surg. 2008 Feb; 18(2):162-6.
-
Renda G, Di Pillo R, D'Alleva A, Sciartilli A, Zimarino M, De Candia E, Landolfi R, Di Giammarco G, Calafiore A, De Caterina R. Surgical bleeding after pre-operative unfractionated heparin and low molecular weight heparin for coronary bypass surgery. Haematologica. 2007 Mar; 92(3):366-73.
-
Michota F, Merli G. Anticoagulation in special patient populations: are special dosing considerations required? Cleve Clin J Med. 2005 Apr; 72 Suppl 1:S37-42.
-
Peyvandi F, De Cristofaro R, Garagiola I, Palla R, Akhavan S, Landolfi R, Mannucci PM. The P303T mutation in the human factor VII (FVII) gene alters the conformational state of the enzyme and causes a severe functional deficiency. Br J Haematol. 2004 Dec; 127(5):576-84.